Multiple studies have demonstrated, when compared to best supportive care, TACE improves survival in HCC patients with a wide range of disease states including CP-A and B, tumor size measuring <14 cm, and multinodular disease (Table 2) (10, 11, 26–30). The gene discussed is CPA1; the disease is hepatocellular carcinoma.